



List of activities within the flexible scope of accreditation

Accredited Body: Unilabs Diagnostics k. s.

CAB Name: Laboratoř forenzní a lékařské genetiky

CAB Number: 8141

Certificate of Accreditation No. 501/2024

Field of Accreditation: Medical Laboratory - ČSN EN ISO 15189 ed. 3:2023

Updated: 26.9.2024

Examinations:

Ordinal Number	Analyte/ parameter/diagnostics	Principle of examination	Identification of method procedure/ equipment	Examined material	Degrees of freedom ¹
816 – Medical Genetics Laboratory					
1.	Examination of germline genome variants	Real-Time PCR	SOP č. 0, v4, SOP-A, v5; CFX 96, CFX Connect	Biological material containing human nuclear DNA	A, B, C
2.	Examination of somatic genome variants	Real-Time PCR	SOP č. 0, v4, SOP-A, v5; CFX 96	Biological material containing human nuclear RNA	A, B, C
3.	Examination of germline genome variants	PCR – fragment analysis, gel	SOP č. 0, v4, SOP-B, v4	Biological material containing human nuclear DNA	A, B, C
4.	Examination of germline genome variants	PCR – fragment analysis, capillary	SOP č. 0, v4, SOP-C, v5; ABI PRISM 3100 Avant; SeqStudio Genetic Analyzer	Biological material containing human nuclear DNA	A, B, C
5.	Examination of germline genome variants	PCR – reverse hybridization	SOP č. 0, v4, SOP-D, v4;	Biological material containing human nuclear DNA	A, B, C
6.	Examination of germline genome variants	Direct sequencing	SOP č. 0, v4, SOP-E, v6; ABI PRISM 3100 Avant; SeqStudio Genetic Analyzer	Biological material containing human nuclear DNA	A, B, C
7.	Examination of germline genome variants	MLPA	SOP č. 0, v4, SOP-F, v6; ABI PRISM 3100 Avant; SeqStudio Genetic Analyzer	Biological material containing human nuclear DNA	A, B, C
8.	Examination of germline genome variants	NGS-MPS	SOP č. 0, v4, SOP-G, v5; Genexus Integrated Sequencer System	Biological material containing human nuclear DNA	A, B, C



List of activities within the flexible scope of accreditation

Specification of the scope of accreditation:

Field Nr. / Ordinal Number	Detailed information on activities within the scope of accreditation
816 /1	<p>Factor V - Leiden mutation (G1691A); Factor II Prothrombin (G20210A); Factor XIII (V34L); Factor V R2 (H1299R); <i>PAI-1</i> (4G/5G); <i>MTHFR</i> (C677T, A1298C); HLA-B*27 – Morbus Bechterew; Lactose intolerance (<i>LCT</i> -13910C>T, -22018G>A); Fructose intolerance (<i>ALDOB</i>: mutations A149P, A174D, N334K, del4E4); α-1 antitrypsin deficiency (<i>SERPINA1</i>: mutations PI*S = E264V, PI*Z = E342K); β-fibrinogen (-455G>A); <i>ApoB</i> (R3500Q); <i>ApoE</i> (E2/E3/E4); <i>GpIIIa</i> (L33P); Metabolism of thiopurine drugs (<i>TPMT</i>: mutations TPMT*2 = G238C, TPTMT*3A = G460A/A719G, TPMT*3B = G460A, TPMT*3C = A719G); Metabolism of warfarin (<i>VKORC1</i>: mutations G1639A, <i>CYP2C9</i>: CYP2C9*2 = C430T, CYP2C9*3 = A1075C); Gilbert syndrome (<i>UGT1A1</i>); Predisposition to celiac sprue (loci <i>DQAI</i> and <i>DQBI</i>; serological equivalents DQ2.5, DQ2.2, DQ8); Hereditary hemochromatosis (<i>HFE</i>: mutations C282Y, H63D, S65C); <i>GpIa</i> (C807T); Determination of predisposition to psoriasis (HLA-C*06 alleles) Metabolism of anticoagulants, antidepressants, antiepileptics, proton pump inhibitors, anticonvulsants, hypnotics, sedatives, antimalarials, antiretrovirics, antifungals and (<i>CYP2C19</i> gene *1, *2, *3, *17 alleles); Metabolism of myorelaxants, e.g. suxamethonium, mivacurium (<i>BCHE</i> gene A, K, F1, F2, S1 alleles); <i>ACE</i> (ins/del)</p>
816/2	Determination of <i>BCR-ABL</i> fusion gene and determination of rearrangement type (M-bcr, m-bcr, μ-bcr)
816/3	Determination of predisposition to celiac sprue (loci <i>DQAI</i> and <i>DQBI</i> ; serological equivalents DQ2.5, DQ2.2, DQ8); Determination of predisposition to narcolepsy (allele DQB1*0602)
816/4	Cystic fibrosis (mutation in <i>CFTR</i> gene); Fragile X syndrome – determination of CGG repeats number in <i>FMRI</i> gene Determination of <i>AZF</i> locus microdeletions on Y chromosome (<i>AZFa</i> , <i>AZFb</i> , <i>AZFc</i>);



List of activities within the flexible scope of accreditation

Field Nr. / Ordinal Number	Detailed information on activities within the scope of accreditation
816/5	Examination of predisposition to rheumatoid arthritis (shared HLA-DRB1 epitope)
816/6.	Copper metabolism (<i>ATP7B</i> - exons 3, 8, 14, 15 and 17); Prelingual hearing loss, non-syndromic (<i>GJB2</i> gene)
816/7	Spinal muscular atrophy (deletion/duplication of exons 7 and 8 in <i>SMN1</i> and <i>SMN2</i> genes); Detection of deletions and duplications in <i>BRCA1</i> gene; Detection of deletions and duplications in <i>BRCA2/CHEK2</i> genes Detection of deletions and duplications in <i>EPCAM</i> , <i>MSH2</i> , <i>MLH1</i> , <i>PMS2</i> , <i>MUTYH</i> a <i>MSH6</i> genes by MLPA method
816/8	Hereditary breast and ovarian cancer (<i>BRCA1</i> and <i>BRCA2</i>) genes; Hereditary breast and ovarian cancer - NGS panel of 21 genes (<i>ATM</i> , <i>BARD1</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>BRIP1</i> , <i>CDH1</i> , <i>CDK12</i> , <i>FAM175A</i> , <i>FANCD2</i> , <i>CHEK2</i> , <i>MRE11</i> , <i>MSH6</i> , <i>NBN</i> , <i>PALB2</i> , <i>PMS2</i> , <i>RAD51B</i> , <i>RAD54L</i> , <i>TP53</i> , <i>RAD50</i> , <i>RAD51C</i> , <i>RAD51D</i>); Hereditary prostate cancer - NGS panel of 26 genes (<i>AKT1</i> , <i>APC</i> , <i>AR</i> , <i>ATM</i> , <i>BRAF</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>CDH1</i> , <i>CDK12</i> , <i>CTNNB1</i> , <i>HOXB13</i> , <i>CHEK2</i> , <i>IDH1</i> , <i>KRAS</i> , <i>MED12</i> , <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>MYC</i> , <i>PIK3CA</i> , <i>PIK3R1</i> , <i>PMS2</i> , <i>PTEN</i> , <i>RB1</i> , <i>SPOP</i> , <i>TP53</i>); Colorectal and pancreatic cancer - NGS panel of 13 genes (<i>APC</i> , <i>BRAF</i> , <i>CTNNB1</i> , <i>KRAS</i> , <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>MYC</i> , <i>PIK3CA</i> , <i>PMS2</i> , <i>PTEN</i> , <i>STK11</i> , <i>TP53</i>); NGS panel of hereditary cancer syndromes - 50 genes (<i>AKT1</i> , <i>APC</i> , <i>AR</i> , <i>ATM</i> , <i>ATR</i> , <i>BARD1</i> , <i>BLM</i> , <i>BRAF</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>BRIP1</i> , <i>CDH1</i> , <i>CDK12</i> , <i>CTNNB1</i> , <i>EPCAM</i> , <i>FAM175A</i> , <i>FANCD2</i> , <i>GATA3</i> , <i>GEN1</i> , <i>HOXB13</i> , <i>CHEK2</i> , <i>IDH1</i> , <i>KRAS</i> , <i>MED12</i> , <i>MLH1</i> , <i>MRE11</i> , <i>MSH2</i> , <i>MSH6</i> , <i>MUTYH</i> , <i>MYC</i> , <i>NBN</i> , <i>NF1</i> , <i>PALB2</i> , <i>PIK3CA</i> , <i>PIK3R1</i> , <i>PMS2</i> , <i>PTEN</i> , <i>RAD50</i> , <i>RAD51B</i> , <i>RAD51C</i> , <i>RAD51D</i> , <i>RAD54L</i> , <i>RB1</i> , <i>RET</i> , <i>SPOP</i> , <i>STK11</i> , <i>TP53</i> , <i>VHL</i> , <i>WT1</i> , <i>XRCC2</i>)

Explanatory notes:

¹ Established degrees of freedom according to MPA 00-09-...:

A – Flexibility concerning the documented examination/ sample collection procedure

B – Flexibility concerning the technique

C – Flexibility concerning the analytes / parameters

D – Flexibility concerning the examined material

If no degree of freedom is specified, the laboratory cannot apply a flexible approach to the scope of accreditation for this examination.

Real-Time PCR Real-Time Polymerase Chain Reaction

MLPA Multiplex ligation-dependent probe amplification

NGS-MPS Next Generation Sequencing – Massively Parallel Sequencing

PCR Polymerase Chain Reaction